IP Library Granted Patent US 11,020,531
Granted Patent B2
US 11,020,531 · App. 16/591,688 · Granted Jun 1, 2021

Silicone free drug delivery devices

Inventors: Edgar G. Ashmead (Lincoln University, PA); Edward C. Gunzel (Oxford, PA); Michael Moritz (Media, PA)
Assignee: W. L. Gore & Associates, Inc.
A61M5/31513A61K35/12A61K38/4846A61M5/3202A61M2005/3118A61M2005/3131A61M2205/0238A61M2207/00Y10T156/1043Y10T428/1321Y10T428/1352Y10T428/1359Y10T428/1376Y10T428/24992Y10T428/3154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,531
App. No.
16/591,688
Granted
Jun 1, 2021
Kind
B2
Abstract

A pre-filled syringe having containing therein at least one therapeutic is provided. The syringe contains a silicone free barrel and an elastomeric syringe stopper that is covered with an expanded polytetrafluoroethylene barrier layer. The presence of a barrier layer that is at least partially porous on the outside of the syringe stopper improves the seal between the stopper and syringe barrel and minimizes the sliding force. In some embodiments, the barrel is formed of a glass material such as a borosilicate glass, that is free of silicone or other lubricants.

Claims (15)

1. A pre-filled syringe comprising:

a silicone free syringe barrel having a first end and a second end;

an elastomeric stopper comprising an elastomer, the elastomeric stopper being positioned within the syringe barrel, creating a volume for containment of at least one therapeutic;

an expanded polytetrafluoroethylene film having a first side and a second side,

wherein the elastomer is at least partially imbibed into the first side of the expanded polytetrafluoroethylene film.

2. The pre-filled syringe of claim 1 , further comprising a needle attached to the first end of said barrel.

3. The pre-filled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and combinations thereof.

4. The pre-filled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and combinations thereof.

5. The prefilled syringe of claim 4 , wherein the therapeutic is anti-ngf.

6. The pre-filled syringe of claim 1 , wherein said therapeutic comprises mutations of a bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and combinations thereof.

7. The prefilled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from protein kinases, esterases, phosphatases, ion channels, proteases, structural proteins, membrane transport proteins, nuclear hormone receptors, and mutations and combinations thereof.

8. The prefilled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and combinations thereof.

9. The prefilled syringe of claim 1 , wherein said therapeutic comprises at least one bioactive selected from primary and embryonic stem cells.

10. The pre-filled syringe of claim 1 , wherein the therapeutic is factor VII.

11. The pre-filled syringe of claim 1 , wherein the therapeutics is used for treatment of ocular disease.

Continuity (5)
Division 15425082 · Feb 6, 2017
Continuation In Part 13117573 · May 27, 2011
Continuation In Part 12915850 · Oct 29, 2010
Provisional Application 61256156 · Oct 29, 2009
Related Publication 20200061298A1 · Feb 27, 2020
Cited By (6)
US 1,116,103 US 1,120,314 US 12,274,865 US 12,434,002 US 12,649,031 US 12,691,227